Show simple item record

dc.contributor.authorCantz, Tobias
dc.contributor.authorSharma, Amar Deep
dc.contributor.authorOtt, Michael
dc.date.accessioned2015-04-23T09:35:22Zen
dc.date.available2015-04-23T09:35:22Zen
dc.date.issued2015-04en
dc.identifier.citationConcise review: cell therapies for hereditary metabolic liver diseases-concepts, clinical results, and future developments. 2015, 33 (4):1055-62 Stem Cellsen
dc.identifier.issn1549-4918en
dc.identifier.pmid25524146en
dc.identifier.doi10.1002/stem.1920en
dc.identifier.urihttp://hdl.handle.net/10033/550489en
dc.description.abstractThe concept of cell-based therapies for inherited metabolic liver diseases has been introduced for now more than 40 years in animal experiments, but controlled clinical data in humans are still not available. In the era of dynamic developments in stem cell science, the "right" cell for transplantation is considered as an important key for successful treatment. Do we aim to transplant mature hepatocytes or do we consider the liver as a stem/progenitor-driven organ and replenish the diseased liver with genetically normal stem/progenitor cells? Although conflicting results from cell tracing and transplantation experiments have recently emerged about the existence and role of stem/progenitor cells in the liver, their overall contribution to parenchymal cell homeostasis and tissue repair is limited. Accordingly, engraftment and repopulation efficacies of extrahepatic and liver-derived stem/progenitor cell types are considered to be lower compared to mature hepatocytes. On the basis of these results, we will discuss the current clinical cell transplantation programs for inherited metabolic liver diseases and future developments in liver cell therapy. Stem Cells 2015;33:1055-1062.
dc.language.isoenen
dc.titleConcise review: cell therapies for hereditary metabolic liver diseases-concepts, clinical results, and future developments.en
dc.typeArticleen
dc.contributor.departmentTWINCORE, Centre for Experimental and Clinical Infection Research, Feodor-Lynen Str. 7, 30625, Hannover, Germany.en
dc.identifier.journalStem cells (Dayton, Ohio)en
refterms.dateFOA2018-06-12T23:38:04Z
html.description.abstractThe concept of cell-based therapies for inherited metabolic liver diseases has been introduced for now more than 40 years in animal experiments, but controlled clinical data in humans are still not available. In the era of dynamic developments in stem cell science, the "right" cell for transplantation is considered as an important key for successful treatment. Do we aim to transplant mature hepatocytes or do we consider the liver as a stem/progenitor-driven organ and replenish the diseased liver with genetically normal stem/progenitor cells? Although conflicting results from cell tracing and transplantation experiments have recently emerged about the existence and role of stem/progenitor cells in the liver, their overall contribution to parenchymal cell homeostasis and tissue repair is limited. Accordingly, engraftment and repopulation efficacies of extrahepatic and liver-derived stem/progenitor cell types are considered to be lower compared to mature hepatocytes. On the basis of these results, we will discuss the current clinical cell transplantation programs for inherited metabolic liver diseases and future developments in liver cell therapy. Stem Cells 2015;33:1055-1062.


Files in this item

Thumbnail
Name:
Cantz, Sharma and Ott_final.pdf
Size:
283.6Kb
Format:
PDF
Description:
original manuscript
Thumbnail
Name:
SC-14-0822_R1_Fig1.jpg
Size:
619.8Kb
Format:
JPEG image
Description:
figure 1
Thumbnail
Name:
SC-14-0822_R1_Fig2.jpg
Size:
342.6Kb
Format:
JPEG image
Description:
figure 2

This item appears in the following Collection(s)

Show simple item record